NCT02007811 - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid LeukemiaNon Hodgkin's LymphomaHodgkin's DiseaseMyelodysplastic SyndromeMultiple MyelomaAplastic Anemia

Interventions

BIOLOGICAL

allogeneic donor derived B-lymphocytes

CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses

Trial Locations (1)

91054

RECRUITING

Medical Department 5, University Hospital Erlangen, Erlangen